Patents by Inventor Martin R. Hodge

Martin R. Hodge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110171205
    Abstract: The invention provides isolated nucleic acids molecules, designated 15571, 2465, 14266, 2882, 52871, 8203 or 16852 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 15571, 2465, 14266, 2882, 52871, 8203 or 16852 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 15571, 2465, 14266, 2882, 52871, 8203 or 16852 gene has been introduced or disrupted. The invention still further provides isolated 15571, 2465, 14266, 2882, 52871, 8203 or 16852 proteins, fusion proteins, antigenic peptides and anti-15571, 2465, 14266, 2882, 52871, 8203 or 16852 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: January 25, 2011
    Publication date: July 14, 2011
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Martin R. Hodge, Clare M. Lloyd, Nadine S. Weich, Jose M. Lora, David White, Maria A. Glucksmann, Keith E. Robison, Inmaculada Silos-Santiago, Andrew D.J. Goodearl, Rory A.J. Curtis
  • Publication number: 20110110915
    Abstract: A novel human kinase protein and nucleic acid molecule are disclosed. In addition to the isolated kinase protein, the invention further provides isolated kinase fusion proteins, antigenic peptides, and anti-kinase antibodies. The invention also provides kinase nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a kinase gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: May 27, 2010
    Publication date: May 12, 2011
    Applicant: MILLENNIUM PHARMACEUTICALS, INC.
    Inventor: Martin R. Hodge
  • Publication number: 20110104706
    Abstract: Novel kinase polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length kinase proteins, the invention further provides isolated kinase fusion proteins, antigenic peptides, and anti-kinase antibodies. The invention also provides kinase nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a kinase gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: December 1, 2009
    Publication date: May 5, 2011
    Applicant: MILLENNIUM PHARMACEUTICALS, INC.
    Inventor: MARTIN R. HODGE
  • Patent number: 7759085
    Abstract: A novel human kinase protein and nucleic acid molecule is disclosed. In addition to the isolated kinase protein, the invention further provides isolated kinase fusion proteins, antigenic peptides, and anti-kinase antibodies. The invention also provides kinase nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a kinase gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: October 14, 2003
    Date of Patent: July 20, 2010
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Martin R. Hodge
  • Patent number: 7655432
    Abstract: Novel kinase polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length kinase proteins, the invention further provides isolated kinase fusion proteins, antigenic peptides, and anti-kinase antibodies. The invention also provides kinase nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a kinase gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: May 7, 2008
    Date of Patent: February 2, 2010
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Martin R. Hodge
  • Publication number: 20090226450
    Abstract: The invention provides isolated nucleic acids molecules, designated 15571, 2465, 14266, 2882, 52871, 8203 or 16852 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 15571, 2465, 14266, 2882, 52871, 8203 or 16852 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 15571, 2465, 14266, 2882, 52871, 8203 or 16852 gene has been introduced or disrupted. The invention still further provides isolated 15571, 2465, 14266, 2882, 52871, 8203 or 16852 proteins, fusion proteins, antigenic peptides and anti-15571, 2465, 14266, 2882, 52871, 8203 or 16852 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: April 23, 2009
    Publication date: September 10, 2009
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Martin R. Hodge, Clare M. Lloyd, Nadine S. Weich, Jose M. Lora, David White, Maria A. Glucksmann, Keith E. Robison, Inmaculada Silos-Santiago, Andrew D.J. Goodearl, Rory A.J. Curtis
  • Publication number: 20090068187
    Abstract: The invention provides isolated nucleic acids molecules, designated 14275, 54420, 8797, 27439, 68730, 69112 or 52908 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 14275, 54420, 8797, 27439, 68730, 69112 or 52908 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 14275, 54420, 8797, 27439, 68730, 69112 or 52908 gene has been introduced or disrupted. The invention still further provides isolated 14275, 54420, 8797, 27439, 68730, 69112 or 52908 proteins, fusion proteins, antigenic peptides and anti-14275, 54420, 8797, 27439, 68730, 69112 or 52908 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: September 24, 2007
    Publication date: March 12, 2009
    Inventors: Maria A. Glucksmann, Rory A.J. Curtis, Fong-Ying Tsai, Martin R. Hodge, Rachel E. Meyers, Kyle J. MacBeth, Rajasekhar Bandaru
  • Publication number: 20080274472
    Abstract: Novel kinase polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length kinase proteins, the invention further provides isolated kinase fusion proteins, antigenic peptides, and anti-kinase antibodies. The invention also provides kinase nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a kinase gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: May 7, 2008
    Publication date: November 6, 2008
    Inventor: Martin R. Hodge
  • Patent number: 7425424
    Abstract: Novel kinase polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length kinase proteins, the invention further provides isolated kinase fusion proteins, antigenic peptides, and anti-kinase antibodies. The invention also provides kinase nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a kinase gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: February 21, 2006
    Date of Patent: September 16, 2008
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Martin R. Hodge
  • Patent number: 7214374
    Abstract: Novel human kinase-like polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length kinase-like proteins, the invention further provides isolated kinase-like fusion proteins, antigenic peptides, and anti-kinase-like antibodies. The invention also provides kinase-like nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a kinase-like gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: October 9, 2003
    Date of Patent: May 8, 2007
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Rachel Meyers, Martin R. Hodge, Mark Williamson
  • Patent number: 6858418
    Abstract: Novel kinase polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length kinase proteins, the invention further provides isolated kinase fusion proteins, antigenic peptides, and anti-kinase antibodies. The invention also provides kinase nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a kinase gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: May 21, 2001
    Date of Patent: February 22, 2005
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Martin R. Hodge
  • Patent number: 6830914
    Abstract: Novel RGS polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length RGS proteins, the invention further provides isolated RGS fusion proteins, antigenic peptides, and anti-RGS antibodies. The invention also provides RGS nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an RGS gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: June 27, 2001
    Date of Patent: December 14, 2004
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Martin R. Hodge, David Yowe
  • Publication number: 20040248160
    Abstract: The invention provides isolated nucleic acids molecules, designated 14275, 54420, 8797, 27439, 68730, 69112 or 52908 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 14275, 54420, 8797, 27439, 68730, 69112 or 52908 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 14275, 54420, 8797, 27439, 68730, 69112 or 52908 gene has been introduced or disrupted. The invention still further provides isolated 14275, 54420, 8797, 27439, 68730, 69112 or 52908 proteins, fusion proteins, antigenic peptides and anti-14275, 54420, 8797, 27439, 68730, 69112 or 52908 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: February 19, 2004
    Publication date: December 9, 2004
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Maria A. Glucksmann, Rory A.J. Curtis, Fong-Ying Tsai, Martin R. Hodge, Rachel E. Meyers, Kyle J. MacBeth, Rajasekhar Bandaru
  • Publication number: 20040147004
    Abstract: Novel human kinase-like polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length kinase-like proteins, the invention further provides isolated kinase-like fusion proteins, antigenic peptides, and anti-kinase-like antibodies. The invention also provides kinase-like nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a kinase-like gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: October 9, 2003
    Publication date: July 29, 2004
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Rachel Meyers, Martin R. Hodge, Mark Williamson
  • Publication number: 20040146939
    Abstract: A novel human kinase protein and nucleic acid molecule is disclosed. In addition to the isolated kinase protein, the invention further provides isolated kinase fusion proteins, antigenic peptides, and anti-kinase antibodies. The invention also provides kinase nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a kinase gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: October 14, 2003
    Publication date: July 29, 2004
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventor: Martin R. Hodge
  • Patent number: 6759221
    Abstract: A novel human kinase protein and nucleic acid molecule is disclosed. In addition to the isolated kinase protein, the invention further provides isolated kinase fusion proteins, antigenic peptides, and anti-kinase antibodies. The invention also provides kinase nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a kinase gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: August 18, 2000
    Date of Patent: July 6, 2004
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Martin R. Hodge
  • Patent number: 6733990
    Abstract: Novel GPCR-like polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length GPCR-like proteins, the invention further provides isolated GPCR-like fusion proteins, antigenic peptides, and anti-GPCR-like antibodies. The invention also provides GPCR-like nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a GPCR-like gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: August 3, 2000
    Date of Patent: May 11, 2004
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Martin R. Hodge, Clare Lloyd, Nadine S. Weich
  • Publication number: 20040024185
    Abstract: Isolated nucleic acid molecules encoding a novel protein, NIP45, that interacts with members of the Nuclear Factor of Activated T cell (NF-AT) family of proteins, are disclosed. The invention further provides antisense nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals carrying a NIP45 transgene. The invention further provides isolated NIP45 proteins and peptides, NIP45 fusion proteins and anti-NIP45 antibodies. Methods of using the NIP45 compositions of the invention are also disclosed, including methods for detecting NIP45 protein or mRNA in a biological sample, methods of modulating NIP45 activity in a cell, and methods for identifying agents that modulate an interaction between NIP45 and an NF-AT family protein.
    Type: Application
    Filed: May 30, 2003
    Publication date: February 5, 2004
    Applicant: President and Fellows of Harvard College
    Inventors: Laurie H. Glimcher, Martin R. Hodge
  • Patent number: 6656698
    Abstract: Novel human kinase-like polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length kinase-like proteins, the invention further provides isolated kinase-like fusion proteins, antigenic peptides, and anti-kinase-like antibodies. The invention also provides kinase-like nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a kinase-like gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: May 1, 2000
    Date of Patent: December 2, 2003
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Rachel Meyers, Martin R. Hodge, Mark Williamson
  • Publication number: 20030162172
    Abstract: The present invention relates to a newly identified G-protein-coupled receptor. The invention also relates to polynucleotides encoding the receptors. The invention further relates to methods using receptor polypeptides and polynucleotides for diagnosis and treatment in receptor-mediated disorders. The invention further relates to methods using the receptor polypeptides and polynucleotides to identify agonists and antagonists useful for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the receptor polypeptides and polynucleotides. The invention further relates to procedures for producing the receptor polypeptides and polynucleotides by recombinant methods.
    Type: Application
    Filed: December 18, 2000
    Publication date: August 28, 2003
    Inventors: Maria Alexandra Glucksmann, Martin R. Hodge, John J. Hunter, Laura Rudolph-Owen, Nadine S. Weich